nodes	percent_of_prediction	percent_of_DWPC	metapath
Carbimazole—TPO—Hematopoietic Stem Cell Differentiation—CSF3—urinary bladder cancer	0.0241	0.127	CbGpPWpGaD
Carbimazole—CYP19A1—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.0147	0.0768	CbGpPWpGaD
Carbimazole—TPO—Amino acid and derivative metabolism—GSTZ1—urinary bladder cancer	0.0118	0.062	CbGpPWpGaD
Carbimazole—CYP19A1—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00702	0.0368	CbGpPWpGaD
Carbimazole—CYP19A1—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00693	0.0363	CbGpPWpGaD
Carbimazole—Discomfort—Mitomycin—urinary bladder cancer	0.0065	0.00803	CcSEcCtD
Carbimazole—Pruritus—Valrubicin—urinary bladder cancer	0.00647	0.008	CcSEcCtD
Carbimazole—Thrombocytopenia—Mitomycin—urinary bladder cancer	0.00617	0.00763	CcSEcCtD
Carbimazole—TPO—Differentiation Pathway—IGF1—urinary bladder cancer	0.00615	0.0323	CbGpPWpGaD
Carbimazole—Mouth ulceration—Etoposide—urinary bladder cancer	0.00577	0.00713	CcSEcCtD
Carbimazole—Rash—Valrubicin—urinary bladder cancer	0.00577	0.00713	CcSEcCtD
Carbimazole—Dermatitis—Valrubicin—urinary bladder cancer	0.00576	0.00712	CcSEcCtD
Carbimazole—Headache—Valrubicin—urinary bladder cancer	0.00573	0.00708	CcSEcCtD
Carbimazole—CYP19A1—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00569	0.0298	CbGpPWpGaD
Carbimazole—Bone marrow depression—Methotrexate—urinary bladder cancer	0.00566	0.007	CcSEcCtD
Carbimazole—Liver disorder—Methotrexate—urinary bladder cancer	0.00561	0.00693	CcSEcCtD
Carbimazole—Haemolytic anaemia—Cisplatin—urinary bladder cancer	0.0056	0.00692	CcSEcCtD
Carbimazole—Nausea—Valrubicin—urinary bladder cancer	0.00543	0.00672	CcSEcCtD
Carbimazole—CYP19A1—Integrated Breast Cancer Pathway—PHB—urinary bladder cancer	0.00538	0.0282	CbGpPWpGaD
Carbimazole—Bone marrow depression—Epirubicin—urinary bladder cancer	0.0053	0.00655	CcSEcCtD
Carbimazole—Pancytopenia—Thiotepa—urinary bladder cancer	0.00529	0.00654	CcSEcCtD
Carbimazole—Feeling abnormal—Mitomycin—urinary bladder cancer	0.00519	0.00642	CcSEcCtD
Carbimazole—Liver function test abnormal—Gemcitabine—urinary bladder cancer	0.00501	0.00619	CcSEcCtD
Carbimazole—Body temperature increased—Mitomycin—urinary bladder cancer	0.00498	0.00616	CcSEcCtD
Carbimazole—CYP19A1—Ovarian Infertility Genes—ESR2—urinary bladder cancer	0.00494	0.0259	CbGpPWpGaD
Carbimazole—Bone marrow depression—Doxorubicin—urinary bladder cancer	0.0049	0.00606	CcSEcCtD
Carbimazole—Stomatitis—Thiotepa—urinary bladder cancer	0.00484	0.00599	CcSEcCtD
Carbimazole—Jaundice—Thiotepa—urinary bladder cancer	0.00484	0.00599	CcSEcCtD
Carbimazole—Agranulocytosis—Thiotepa—urinary bladder cancer	0.00464	0.00573	CcSEcCtD
Carbimazole—Eosinophilia—Fluorouracil—urinary bladder cancer	0.00456	0.00564	CcSEcCtD
Carbimazole—Haemoglobin—Thiotepa—urinary bladder cancer	0.00448	0.00554	CcSEcCtD
Carbimazole—Haemorrhage—Thiotepa—urinary bladder cancer	0.00446	0.00551	CcSEcCtD
Carbimazole—Pancytopenia—Gemcitabine—urinary bladder cancer	0.00445	0.0055	CcSEcCtD
Carbimazole—Ageusia—Epirubicin—urinary bladder cancer	0.00442	0.00546	CcSEcCtD
Carbimazole—Neutropenia—Gemcitabine—urinary bladder cancer	0.00438	0.00542	CcSEcCtD
Carbimazole—Pancytopenia—Fluorouracil—urinary bladder cancer	0.00438	0.00541	CcSEcCtD
Carbimazole—Pancytopenia—Cisplatin—urinary bladder cancer	0.00415	0.00513	CcSEcCtD
Carbimazole—Ageusia—Doxorubicin—urinary bladder cancer	0.00409	0.00505	CcSEcCtD
Carbimazole—Stomatitis—Gemcitabine—urinary bladder cancer	0.00407	0.00504	CcSEcCtD
Carbimazole—Jaundice cholestatic—Epirubicin—urinary bladder cancer	0.00407	0.00503	CcSEcCtD
Carbimazole—Angiopathy—Thiotepa—urinary bladder cancer	0.00405	0.005	CcSEcCtD
Carbimazole—Stomatitis—Fluorouracil—urinary bladder cancer	0.00401	0.00495	CcSEcCtD
Carbimazole—Rash—Mitomycin—urinary bladder cancer	0.00397	0.00491	CcSEcCtD
Carbimazole—Dermatitis—Mitomycin—urinary bladder cancer	0.00397	0.00491	CcSEcCtD
Carbimazole—TPO—Amino acid and derivative metabolism—NQO1—urinary bladder cancer	0.00396	0.0208	CbGpPWpGaD
Carbimazole—Headache—Mitomycin—urinary bladder cancer	0.00395	0.00488	CcSEcCtD
Carbimazole—Alopecia—Thiotepa—urinary bladder cancer	0.00394	0.00487	CcSEcCtD
Carbimazole—Agranulocytosis—Gemcitabine—urinary bladder cancer	0.0039	0.00482	CcSEcCtD
Carbimazole—CYP19A1—Biological oxidations—GSTZ1—urinary bladder cancer	0.00387	0.0203	CbGpPWpGaD
Carbimazole—Agranulocytosis—Fluorouracil—urinary bladder cancer	0.00384	0.00474	CcSEcCtD
Carbimazole—CYP19A1—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00382	0.02	CbGpPWpGaD
Carbimazole—CYP19A1—Ovarian Infertility Genes—NCOR1—urinary bladder cancer	0.00382	0.02	CbGpPWpGaD
Carbimazole—Pancytopenia—Etoposide—urinary bladder cancer	0.0038	0.0047	CcSEcCtD
Carbimazole—Stomatitis—Cisplatin—urinary bladder cancer	0.0038	0.00469	CcSEcCtD
Carbimazole—Haemoglobin—Gemcitabine—urinary bladder cancer	0.00377	0.00466	CcSEcCtD
Carbimazole—Jaundice cholestatic—Doxorubicin—urinary bladder cancer	0.00377	0.00465	CcSEcCtD
Carbimazole—Haemorrhage—Gemcitabine—urinary bladder cancer	0.00375	0.00464	CcSEcCtD
Carbimazole—Neutropenia—Etoposide—urinary bladder cancer	0.00374	0.00463	CcSEcCtD
Carbimazole—Nausea—Mitomycin—urinary bladder cancer	0.00374	0.00463	CcSEcCtD
Carbimazole—Haemoglobin—Fluorouracil—urinary bladder cancer	0.00371	0.00458	CcSEcCtD
Carbimazole—Haemorrhage—Fluorouracil—urinary bladder cancer	0.00369	0.00456	CcSEcCtD
Carbimazole—CYP19A1—Biological oxidations—GSTO2—urinary bladder cancer	0.00367	0.0192	CbGpPWpGaD
Carbimazole—CYP19A1—Biological oxidations—NAT1—urinary bladder cancer	0.00367	0.0192	CbGpPWpGaD
Carbimazole—CYP19A1—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.00362	0.019	CbGpPWpGaD
Carbimazole—Aplastic anaemia—Methotrexate—urinary bladder cancer	0.00359	0.00443	CcSEcCtD
Carbimazole—Hepatocellular injury—Epirubicin—urinary bladder cancer	0.00358	0.00442	CcSEcCtD
Carbimazole—Stomatitis—Etoposide—urinary bladder cancer	0.00348	0.0043	CcSEcCtD
Carbimazole—Jaundice—Etoposide—urinary bladder cancer	0.00348	0.0043	CcSEcCtD
Carbimazole—Leukopenia—Thiotepa—urinary bladder cancer	0.00348	0.0043	CcSEcCtD
Carbimazole—Mouth ulceration—Methotrexate—urinary bladder cancer	0.00346	0.00427	CcSEcCtD
Carbimazole—Angiopathy—Gemcitabine—urinary bladder cancer	0.0034	0.00421	CcSEcCtD
Carbimazole—Aplastic anaemia—Epirubicin—urinary bladder cancer	0.00336	0.00415	CcSEcCtD
Carbimazole—CYP19A1—Biological oxidations—UGT2B7—urinary bladder cancer	0.00336	0.0176	CbGpPWpGaD
Carbimazole—Agranulocytosis—Etoposide—urinary bladder cancer	0.00333	0.00412	CcSEcCtD
Carbimazole—Alopecia—Gemcitabine—urinary bladder cancer	0.00332	0.0041	CcSEcCtD
Carbimazole—CYP19A1—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00331	0.0174	CbGpPWpGaD
Carbimazole—Hepatocellular injury—Doxorubicin—urinary bladder cancer	0.00331	0.00409	CcSEcCtD
Carbimazole—Arthralgia—Thiotepa—urinary bladder cancer	0.00331	0.00409	CcSEcCtD
Carbimazole—Myalgia—Thiotepa—urinary bladder cancer	0.00331	0.00409	CcSEcCtD
Carbimazole—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.00328	0.00406	CcSEcCtD
Carbimazole—Alopecia—Fluorouracil—urinary bladder cancer	0.00326	0.00403	CcSEcCtD
Carbimazole—Mouth ulceration—Epirubicin—urinary bladder cancer	0.00323	0.004	CcSEcCtD
Carbimazole—Infection—Thiotepa—urinary bladder cancer	0.00315	0.00389	CcSEcCtD
Carbimazole—Nervous system disorder—Thiotepa—urinary bladder cancer	0.00311	0.00384	CcSEcCtD
Carbimazole—Aplastic anaemia—Doxorubicin—urinary bladder cancer	0.00311	0.00384	CcSEcCtD
Carbimazole—Thrombocytopenia—Thiotepa—urinary bladder cancer	0.0031	0.00383	CcSEcCtD
Carbimazole—Alopecia—Cisplatin—urinary bladder cancer	0.00309	0.00382	CcSEcCtD
Carbimazole—Skin disorder—Thiotepa—urinary bladder cancer	0.00308	0.0038	CcSEcCtD
Carbimazole—Ill-defined disorder—Gemcitabine—urinary bladder cancer	0.00303	0.00375	CcSEcCtD
Carbimazole—CYP19A1—Biological oxidations—CYP4B1—urinary bladder cancer	0.00302	0.0158	CbGpPWpGaD
Carbimazole—CYP19A1—Ovarian Infertility Genes—ATM—urinary bladder cancer	0.00302	0.0158	CbGpPWpGaD
Carbimazole—CYP19A1—Ovarian Infertility Genes—CDK4—urinary bladder cancer	0.00301	0.0158	CbGpPWpGaD
Carbimazole—Mouth ulceration—Doxorubicin—urinary bladder cancer	0.00299	0.0037	CcSEcCtD
Carbimazole—CYP19A1—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00298	0.0156	CbGpPWpGaD
Carbimazole—Malaise—Gemcitabine—urinary bladder cancer	0.00295	0.00364	CcSEcCtD
Carbimazole—Leukopenia—Gemcitabine—urinary bladder cancer	0.00292	0.00361	CcSEcCtD
Carbimazole—Angiopathy—Etoposide—urinary bladder cancer	0.00291	0.00359	CcSEcCtD
Carbimazole—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.00289	0.00357	CcSEcCtD
Carbimazole—Leukopenia—Fluorouracil—urinary bladder cancer	0.00288	0.00355	CcSEcCtD
Carbimazole—Alopecia—Etoposide—urinary bladder cancer	0.00283	0.0035	CcSEcCtD
Carbimazole—Ill-defined disorder—Cisplatin—urinary bladder cancer	0.00283	0.00349	CcSEcCtD
Carbimazole—Myalgia—Gemcitabine—urinary bladder cancer	0.00278	0.00344	CcSEcCtD
Carbimazole—Arthralgia—Gemcitabine—urinary bladder cancer	0.00278	0.00344	CcSEcCtD
Carbimazole—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.00276	0.00341	CcSEcCtD
Carbimazole—Discomfort—Gemcitabine—urinary bladder cancer	0.00275	0.0034	CcSEcCtD
Carbimazole—Malaise—Cisplatin—urinary bladder cancer	0.00275	0.00339	CcSEcCtD
Carbimazole—Myalgia—Fluorouracil—urinary bladder cancer	0.00273	0.00338	CcSEcCtD
Carbimazole—Leukopenia—Cisplatin—urinary bladder cancer	0.00273	0.00337	CcSEcCtD
Carbimazole—Discomfort—Fluorouracil—urinary bladder cancer	0.0027	0.00334	CcSEcCtD
Carbimazole—Infection—Gemcitabine—urinary bladder cancer	0.00265	0.00327	CcSEcCtD
Carbimazole—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.00261	0.00323	CcSEcCtD
Carbimazole—Feeling abnormal—Thiotepa—urinary bladder cancer	0.00261	0.00323	CcSEcCtD
Carbimazole—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.00261	0.00323	CcSEcCtD
Carbimazole—Infection—Fluorouracil—urinary bladder cancer	0.0026	0.00322	CcSEcCtD
Carbimazole—Myalgia—Cisplatin—urinary bladder cancer	0.00259	0.0032	CcSEcCtD
Carbimazole—Skin disorder—Gemcitabine—urinary bladder cancer	0.00259	0.0032	CcSEcCtD
Carbimazole—Ill-defined disorder—Etoposide—urinary bladder cancer	0.00259	0.0032	CcSEcCtD
Carbimazole—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.00257	0.00318	CcSEcCtD
Carbimazole—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.00257	0.00318	CcSEcCtD
Carbimazole—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.00257	0.00317	CcSEcCtD
Carbimazole—Liver function test abnormal—Methotrexate—urinary bladder cancer	0.00256	0.00317	CcSEcCtD
Carbimazole—Discomfort—Cisplatin—urinary bladder cancer	0.00256	0.00317	CcSEcCtD
Carbimazole—Urticaria—Thiotepa—urinary bladder cancer	0.00252	0.00311	CcSEcCtD
Carbimazole—Malaise—Etoposide—urinary bladder cancer	0.00252	0.00311	CcSEcCtD
Carbimazole—Body temperature increased—Thiotepa—urinary bladder cancer	0.00251	0.0031	CcSEcCtD
Carbimazole—Leukopenia—Etoposide—urinary bladder cancer	0.0025	0.00309	CcSEcCtD
Carbimazole—Infection—Cisplatin—urinary bladder cancer	0.00247	0.00305	CcSEcCtD
Carbimazole—Nervous system disorder—Cisplatin—urinary bladder cancer	0.00244	0.00301	CcSEcCtD
Carbimazole—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.00243	0.00301	CcSEcCtD
Carbimazole—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.00243	0.003	CcSEcCtD
Carbimazole—Skin disorder—Cisplatin—urinary bladder cancer	0.00241	0.00298	CcSEcCtD
Carbimazole—Liver function test abnormal—Epirubicin—urinary bladder cancer	0.0024	0.00296	CcSEcCtD
Carbimazole—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.00239	0.00295	CcSEcCtD
Carbimazole—Eosinophilia—Methotrexate—urinary bladder cancer	0.00237	0.00293	CcSEcCtD
Carbimazole—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.00236	0.00291	CcSEcCtD
Carbimazole—Discomfort—Etoposide—urinary bladder cancer	0.00235	0.0029	CcSEcCtD
Carbimazole—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00234	0.00289	CcSEcCtD
Carbimazole—Pancytopenia—Methotrexate—urinary bladder cancer	0.00228	0.00281	CcSEcCtD
Carbimazole—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.00226	0.0028	CcSEcCtD
Carbimazole—Infection—Etoposide—urinary bladder cancer	0.00226	0.0028	CcSEcCtD
Carbimazole—Neutropenia—Methotrexate—urinary bladder cancer	0.00224	0.00277	CcSEcCtD
Carbimazole—Pruritus—Thiotepa—urinary bladder cancer	0.00224	0.00277	CcSEcCtD
Carbimazole—Thrombocytopenia—Etoposide—urinary bladder cancer	0.00223	0.00275	CcSEcCtD
Carbimazole—Eosinophilia—Epirubicin—urinary bladder cancer	0.00222	0.00275	CcSEcCtD
Carbimazole—Liver function test abnormal—Doxorubicin—urinary bladder cancer	0.00222	0.00274	CcSEcCtD
Carbimazole—Skin disorder—Etoposide—urinary bladder cancer	0.00221	0.00273	CcSEcCtD
Carbimazole—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.0022	0.00272	CcSEcCtD
Carbimazole—TPO—Metabolism—GSTZ1—urinary bladder cancer	0.00217	0.0114	CbGpPWpGaD
Carbimazole—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.00216	0.00267	CcSEcCtD
Carbimazole—Pancytopenia—Epirubicin—urinary bladder cancer	0.00213	0.00263	CcSEcCtD
Carbimazole—Body temperature increased—Gemcitabine—urinary bladder cancer	0.00211	0.0026	CcSEcCtD
Carbimazole—Neutropenia—Epirubicin—urinary bladder cancer	0.0021	0.00259	CcSEcCtD
Carbimazole—Stomatitis—Methotrexate—urinary bladder cancer	0.00208	0.00258	CcSEcCtD
Carbimazole—Urticaria—Fluorouracil—urinary bladder cancer	0.00208	0.00257	CcSEcCtD
Carbimazole—Body temperature increased—Fluorouracil—urinary bladder cancer	0.00207	0.00256	CcSEcCtD
Carbimazole—TPO—Metabolism—GSTO2—urinary bladder cancer	0.00206	0.0108	CbGpPWpGaD
Carbimazole—TPO—Metabolism—NAT1—urinary bladder cancer	0.00206	0.0108	CbGpPWpGaD
Carbimazole—Eosinophilia—Doxorubicin—urinary bladder cancer	0.00206	0.00254	CcSEcCtD
Carbimazole—Feeling abnormal—Cisplatin—urinary bladder cancer	0.00205	0.00253	CcSEcCtD
Carbimazole—CYP19A1—Biological oxidations—NAT2—urinary bladder cancer	0.00201	0.0105	CbGpPWpGaD
Carbimazole—Rash—Thiotepa—urinary bladder cancer	0.002	0.00247	CcSEcCtD
Carbimazole—Dermatitis—Thiotepa—urinary bladder cancer	0.002	0.00247	CcSEcCtD
Carbimazole—Agranulocytosis—Methotrexate—urinary bladder cancer	0.002	0.00247	CcSEcCtD
Carbimazole—CYP19A1—FSH signaling pathway—SRC—urinary bladder cancer	0.00199	0.0104	CbGpPWpGaD
Carbimazole—Headache—Thiotepa—urinary bladder cancer	0.00199	0.00245	CcSEcCtD
Carbimazole—CYP19A1—Metapathway biotransformation—NAT2—urinary bladder cancer	0.00198	0.0104	CbGpPWpGaD
Carbimazole—Pancytopenia—Doxorubicin—urinary bladder cancer	0.00197	0.00244	CcSEcCtD
Carbimazole—Body temperature increased—Cisplatin—urinary bladder cancer	0.00196	0.00243	CcSEcCtD
Carbimazole—Jaundice—Epirubicin—urinary bladder cancer	0.00195	0.00241	CcSEcCtD
Carbimazole—Stomatitis—Epirubicin—urinary bladder cancer	0.00195	0.00241	CcSEcCtD
Carbimazole—Neutropenia—Doxorubicin—urinary bladder cancer	0.00194	0.0024	CcSEcCtD
Carbimazole—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00193	0.00239	CcSEcCtD
Carbimazole—Haemoglobin—Methotrexate—urinary bladder cancer	0.00193	0.00238	CcSEcCtD
Carbimazole—Haemorrhage—Methotrexate—urinary bladder cancer	0.00192	0.00237	CcSEcCtD
Carbimazole—Hepatitis—Methotrexate—urinary bladder cancer	0.00192	0.00237	CcSEcCtD
Carbimazole—Pruritus—Gemcitabine—urinary bladder cancer	0.00189	0.00233	CcSEcCtD
Carbimazole—TPO—Metabolism—UGT2B7—urinary bladder cancer	0.00188	0.00988	CbGpPWpGaD
Carbimazole—Nausea—Thiotepa—urinary bladder cancer	0.00188	0.00233	CcSEcCtD
Carbimazole—Feeling abnormal—Etoposide—urinary bladder cancer	0.00188	0.00232	CcSEcCtD
Carbimazole—Agranulocytosis—Epirubicin—urinary bladder cancer	0.00187	0.00231	CcSEcCtD
Carbimazole—Pruritus—Fluorouracil—urinary bladder cancer	0.00185	0.00229	CcSEcCtD
Carbimazole—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00183	0.00226	CcSEcCtD
Carbimazole—Urticaria—Etoposide—urinary bladder cancer	0.00181	0.00224	CcSEcCtD
Carbimazole—Haemoglobin—Epirubicin—urinary bladder cancer	0.00181	0.00223	CcSEcCtD
Carbimazole—Stomatitis—Doxorubicin—urinary bladder cancer	0.0018	0.00223	CcSEcCtD
Carbimazole—Jaundice—Doxorubicin—urinary bladder cancer	0.0018	0.00223	CcSEcCtD
Carbimazole—Body temperature increased—Etoposide—urinary bladder cancer	0.0018	0.00222	CcSEcCtD
Carbimazole—Haemorrhage—Epirubicin—urinary bladder cancer	0.0018	0.00222	CcSEcCtD
Carbimazole—Hepatitis—Epirubicin—urinary bladder cancer	0.0018	0.00222	CcSEcCtD
Carbimazole—Angiopathy—Methotrexate—urinary bladder cancer	0.00174	0.00215	CcSEcCtD
Carbimazole—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.00173	0.00214	CcSEcCtD
Carbimazole—TPO—Metabolism—CYP4B1—urinary bladder cancer	0.0017	0.00889	CbGpPWpGaD
Carbimazole—Alopecia—Methotrexate—urinary bladder cancer	0.0017	0.0021	CcSEcCtD
Carbimazole—Rash—Gemcitabine—urinary bladder cancer	0.00168	0.00208	CcSEcCtD
Carbimazole—Dermatitis—Gemcitabine—urinary bladder cancer	0.00168	0.00208	CcSEcCtD
Carbimazole—Hypersensitivity—Etoposide—urinary bladder cancer	0.00168	0.00207	CcSEcCtD
Carbimazole—Haemoglobin—Doxorubicin—urinary bladder cancer	0.00167	0.00206	CcSEcCtD
Carbimazole—Headache—Gemcitabine—urinary bladder cancer	0.00167	0.00206	CcSEcCtD
Carbimazole—Haemorrhage—Doxorubicin—urinary bladder cancer	0.00166	0.00205	CcSEcCtD
Carbimazole—Hepatitis—Doxorubicin—urinary bladder cancer	0.00166	0.00205	CcSEcCtD
Carbimazole—Rash—Fluorouracil—urinary bladder cancer	0.00165	0.00204	CcSEcCtD
Carbimazole—Dermatitis—Fluorouracil—urinary bladder cancer	0.00165	0.00204	CcSEcCtD
Carbimazole—Headache—Fluorouracil—urinary bladder cancer	0.00164	0.00203	CcSEcCtD
Carbimazole—Angiopathy—Epirubicin—urinary bladder cancer	0.00163	0.00201	CcSEcCtD
Carbimazole—Pruritus—Etoposide—urinary bladder cancer	0.00161	0.00199	CcSEcCtD
Carbimazole—CYP19A1—Biological oxidations—HPGDS—urinary bladder cancer	0.00161	0.00843	CbGpPWpGaD
Carbimazole—TPO—Metabolism—SLC19A1—urinary bladder cancer	0.0016	0.0084	CbGpPWpGaD
Carbimazole—CYP19A1—Integrated Breast Cancer Pathway—TSC1—urinary bladder cancer	0.00159	0.00834	CbGpPWpGaD
Carbimazole—Alopecia—Epirubicin—urinary bladder cancer	0.00159	0.00196	CcSEcCtD
Carbimazole—Nausea—Gemcitabine—urinary bladder cancer	0.00158	0.00196	CcSEcCtD
Carbimazole—Rash—Cisplatin—urinary bladder cancer	0.00157	0.00194	CcSEcCtD
Carbimazole—Dermatitis—Cisplatin—urinary bladder cancer	0.00157	0.00193	CcSEcCtD
Carbimazole—TPO—Metabolism—PRSS3—urinary bladder cancer	0.00156	0.00818	CbGpPWpGaD
Carbimazole—CYP19A1—Biological oxidations—GSTT1—urinary bladder cancer	0.00156	0.00818	CbGpPWpGaD
Carbimazole—Nausea—Fluorouracil—urinary bladder cancer	0.00156	0.00192	CcSEcCtD
Carbimazole—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.00155	0.00192	CcSEcCtD
Carbimazole—Angiopathy—Doxorubicin—urinary bladder cancer	0.00151	0.00186	CcSEcCtD
Carbimazole—Malaise—Methotrexate—urinary bladder cancer	0.00151	0.00186	CcSEcCtD
Carbimazole—Leukopenia—Methotrexate—urinary bladder cancer	0.0015	0.00185	CcSEcCtD
Carbimazole—Nausea—Cisplatin—urinary bladder cancer	0.00148	0.00182	CcSEcCtD
Carbimazole—Alopecia—Doxorubicin—urinary bladder cancer	0.00147	0.00181	CcSEcCtD
Carbimazole—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.00145	0.00179	CcSEcCtD
Carbimazole—Rash—Etoposide—urinary bladder cancer	0.00144	0.00177	CcSEcCtD
Carbimazole—Dermatitis—Etoposide—urinary bladder cancer	0.00143	0.00177	CcSEcCtD
Carbimazole—Headache—Etoposide—urinary bladder cancer	0.00143	0.00176	CcSEcCtD
Carbimazole—Arthralgia—Methotrexate—urinary bladder cancer	0.00142	0.00176	CcSEcCtD
Carbimazole—Myalgia—Methotrexate—urinary bladder cancer	0.00142	0.00176	CcSEcCtD
Carbimazole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.00141	0.00175	CcSEcCtD
Carbimazole—Malaise—Epirubicin—urinary bladder cancer	0.00141	0.00174	CcSEcCtD
Carbimazole—Discomfort—Methotrexate—urinary bladder cancer	0.00141	0.00174	CcSEcCtD
Carbimazole—Leukopenia—Epirubicin—urinary bladder cancer	0.0014	0.00173	CcSEcCtD
Carbimazole—Infection—Methotrexate—urinary bladder cancer	0.00135	0.00167	CcSEcCtD
Carbimazole—Nausea—Etoposide—urinary bladder cancer	0.00135	0.00167	CcSEcCtD
Carbimazole—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.00134	0.00166	CcSEcCtD
Carbimazole—Nervous system disorder—Methotrexate—urinary bladder cancer	0.00134	0.00165	CcSEcCtD
Carbimazole—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.00134	0.00165	CcSEcCtD
Carbimazole—Myalgia—Epirubicin—urinary bladder cancer	0.00133	0.00165	CcSEcCtD
Carbimazole—Arthralgia—Epirubicin—urinary bladder cancer	0.00133	0.00165	CcSEcCtD
Carbimazole—Skin disorder—Methotrexate—urinary bladder cancer	0.00132	0.00164	CcSEcCtD
Carbimazole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.00132	0.00163	CcSEcCtD
Carbimazole—Discomfort—Epirubicin—urinary bladder cancer	0.00132	0.00163	CcSEcCtD
Carbimazole—Malaise—Doxorubicin—urinary bladder cancer	0.0013	0.00161	CcSEcCtD
Carbimazole—Leukopenia—Doxorubicin—urinary bladder cancer	0.0013	0.0016	CcSEcCtD
Carbimazole—Infection—Epirubicin—urinary bladder cancer	0.00127	0.00157	CcSEcCtD
Carbimazole—Nervous system disorder—Epirubicin—urinary bladder cancer	0.00125	0.00155	CcSEcCtD
Carbimazole—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.00125	0.00154	CcSEcCtD
Carbimazole—TPO—Metabolism—TYMP—urinary bladder cancer	0.00125	0.00654	CbGpPWpGaD
Carbimazole—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.00124	0.00154	CcSEcCtD
Carbimazole—Skin disorder—Epirubicin—urinary bladder cancer	0.00124	0.00153	CcSEcCtD
Carbimazole—Arthralgia—Doxorubicin—urinary bladder cancer	0.00123	0.00152	CcSEcCtD
Carbimazole—Myalgia—Doxorubicin—urinary bladder cancer	0.00123	0.00152	CcSEcCtD
Carbimazole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.00122	0.00151	CcSEcCtD
Carbimazole—Discomfort—Doxorubicin—urinary bladder cancer	0.00122	0.0015	CcSEcCtD
Carbimazole—Infection—Doxorubicin—urinary bladder cancer	0.00117	0.00145	CcSEcCtD
Carbimazole—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.00116	0.00144	CcSEcCtD
Carbimazole—CYP19A1—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.00116	0.00609	CbGpPWpGaD
Carbimazole—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.00116	0.00143	CcSEcCtD
Carbimazole—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.00116	0.00143	CcSEcCtD
Carbimazole—Skin disorder—Doxorubicin—urinary bladder cancer	0.00115	0.00142	CcSEcCtD
Carbimazole—TPO—Metabolism—NAT2—urinary bladder cancer	0.00113	0.00592	CbGpPWpGaD
Carbimazole—Feeling abnormal—Methotrexate—urinary bladder cancer	0.00112	0.00139	CcSEcCtD
Carbimazole—Urticaria—Methotrexate—urinary bladder cancer	0.00108	0.00134	CcSEcCtD
Carbimazole—CYP19A1—Biological oxidations—GSTP1—urinary bladder cancer	0.00108	0.00567	CbGpPWpGaD
Carbimazole—Body temperature increased—Methotrexate—urinary bladder cancer	0.00108	0.00133	CcSEcCtD
Carbimazole—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.00108	0.00133	CcSEcCtD
Carbimazole—CYP19A1—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.00107	0.00559	CbGpPWpGaD
Carbimazole—Feeling abnormal—Epirubicin—urinary bladder cancer	0.00105	0.0013	CcSEcCtD
Carbimazole—Urticaria—Epirubicin—urinary bladder cancer	0.00101	0.00125	CcSEcCtD
Carbimazole—Body temperature increased—Epirubicin—urinary bladder cancer	0.00101	0.00125	CcSEcCtD
Carbimazole—Hypersensitivity—Methotrexate—urinary bladder cancer	0.001	0.00124	CcSEcCtD
Carbimazole—CYP19A1—Biological oxidations—GSTM1—urinary bladder cancer	0.000994	0.00521	CbGpPWpGaD
Carbimazole—CYP19A1—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.00098	0.00514	CbGpPWpGaD
Carbimazole—TPO—Metabolism—RRM2—urinary bladder cancer	0.000974	0.00511	CbGpPWpGaD
Carbimazole—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000973	0.0012	CcSEcCtD
Carbimazole—Pruritus—Methotrexate—urinary bladder cancer	0.000965	0.00119	CcSEcCtD
Carbimazole—Hypersensitivity—Epirubicin—urinary bladder cancer	0.00094	0.00116	CcSEcCtD
Carbimazole—Urticaria—Doxorubicin—urinary bladder cancer	0.000938	0.00116	CcSEcCtD
Carbimazole—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000933	0.00115	CcSEcCtD
Carbimazole—Pruritus—Epirubicin—urinary bladder cancer	0.000903	0.00112	CcSEcCtD
Carbimazole—TPO—Metabolism—ENO2—urinary bladder cancer	0.000902	0.00473	CbGpPWpGaD
Carbimazole—TPO—Metabolism—HPGDS—urinary bladder cancer	0.000902	0.00473	CbGpPWpGaD
Carbimazole—TPO—Metabolism—GSTT1—urinary bladder cancer	0.000875	0.00459	CbGpPWpGaD
Carbimazole—CYP19A1—Integrated Breast Cancer Pathway—ATM—urinary bladder cancer	0.000873	0.00458	CbGpPWpGaD
Carbimazole—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.00087	0.00108	CcSEcCtD
Carbimazole—CYP19A1—Integrated Breast Cancer Pathway—CDK4—urinary bladder cancer	0.00087	0.00456	CbGpPWpGaD
Carbimazole—CYP19A1—Integrated Breast Cancer Pathway—ESR1—urinary bladder cancer	0.000866	0.00454	CbGpPWpGaD
Carbimazole—Rash—Methotrexate—urinary bladder cancer	0.00086	0.00106	CcSEcCtD
Carbimazole—Dermatitis—Methotrexate—urinary bladder cancer	0.000859	0.00106	CcSEcCtD
Carbimazole—Headache—Methotrexate—urinary bladder cancer	0.000854	0.00106	CcSEcCtD
Carbimazole—Pruritus—Doxorubicin—urinary bladder cancer	0.000835	0.00103	CcSEcCtD
Carbimazole—Nausea—Methotrexate—urinary bladder cancer	0.00081	0.001	CcSEcCtD
Carbimazole—Rash—Epirubicin—urinary bladder cancer	0.000805	0.000994	CcSEcCtD
Carbimazole—Dermatitis—Epirubicin—urinary bladder cancer	0.000804	0.000993	CcSEcCtD
Carbimazole—Headache—Epirubicin—urinary bladder cancer	0.0008	0.000988	CcSEcCtD
Carbimazole—Nausea—Epirubicin—urinary bladder cancer	0.000758	0.000937	CcSEcCtD
Carbimazole—CYP19A1—Integrated Breast Cancer Pathway—RB1—urinary bladder cancer	0.000756	0.00396	CbGpPWpGaD
Carbimazole—CYP19A1—Integrated Breast Cancer Pathway—CDH1—urinary bladder cancer	0.000754	0.00395	CbGpPWpGaD
Carbimazole—Rash—Doxorubicin—urinary bladder cancer	0.000745	0.00092	CcSEcCtD
Carbimazole—Dermatitis—Doxorubicin—urinary bladder cancer	0.000744	0.000919	CcSEcCtD
Carbimazole—Headache—Doxorubicin—urinary bladder cancer	0.00074	0.000914	CcSEcCtD
Carbimazole—TPO—Metabolism—NQO1—urinary bladder cancer	0.000727	0.00381	CbGpPWpGaD
Carbimazole—Nausea—Doxorubicin—urinary bladder cancer	0.000701	0.000867	CcSEcCtD
Carbimazole—CYP19A1—Metabolism—GSTZ1—urinary bladder cancer	0.000662	0.00347	CbGpPWpGaD
Carbimazole—CYP19A1—Metabolism—GSTO2—urinary bladder cancer	0.000628	0.00329	CbGpPWpGaD
Carbimazole—CYP19A1—Metabolism—NAT1—urinary bladder cancer	0.000628	0.00329	CbGpPWpGaD
Carbimazole—CYP19A1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000618	0.00324	CbGpPWpGaD
Carbimazole—TPO—Metabolism—GSTP1—urinary bladder cancer	0.000607	0.00318	CbGpPWpGaD
Carbimazole—CYP19A1—Metabolism—UGT2B7—urinary bladder cancer	0.000574	0.00301	CbGpPWpGaD
Carbimazole—TPO—Metabolism—TYMS—urinary bladder cancer	0.000564	0.00296	CbGpPWpGaD
Carbimazole—CYP19A1—Integrated Breast Cancer Pathway—CCND1—urinary bladder cancer	0.000562	0.00294	CbGpPWpGaD
Carbimazole—TPO—Metabolism—NCOR1—urinary bladder cancer	0.000558	0.00292	CbGpPWpGaD
Carbimazole—TPO—Metabolism—GSTM1—urinary bladder cancer	0.000558	0.00292	CbGpPWpGaD
Carbimazole—CYP19A1—Integrated Breast Cancer Pathway—PTEN—urinary bladder cancer	0.000542	0.00284	CbGpPWpGaD
Carbimazole—TPO—Metabolism—GPX1—urinary bladder cancer	0.000534	0.0028	CbGpPWpGaD
Carbimazole—TPO—Metabolism—ERCC2—urinary bladder cancer	0.000524	0.00275	CbGpPWpGaD
Carbimazole—CYP19A1—Metabolism—CYP4B1—urinary bladder cancer	0.000517	0.00271	CbGpPWpGaD
Carbimazole—CYP19A1—Integrated Breast Cancer Pathway—EP300—urinary bladder cancer	0.000517	0.00271	CbGpPWpGaD
Carbimazole—TPO—Metabolism—MTHFR—urinary bladder cancer	0.000493	0.00258	CbGpPWpGaD
Carbimazole—CYP19A1—Metabolism—SLC19A1—urinary bladder cancer	0.000488	0.00256	CbGpPWpGaD
Carbimazole—CYP19A1—Metabolism—PRSS3—urinary bladder cancer	0.000476	0.00249	CbGpPWpGaD
Carbimazole—CYP19A1—Integrated Breast Cancer Pathway—MYC—urinary bladder cancer	0.000451	0.00236	CbGpPWpGaD
Carbimazole—CYP19A1—Integrated Breast Cancer Pathway—EGFR—urinary bladder cancer	0.000441	0.00231	CbGpPWpGaD
Carbimazole—CYP19A1—Integrated Breast Cancer Pathway—KRAS—urinary bladder cancer	0.000416	0.00218	CbGpPWpGaD
Carbimazole—TPO—Metabolism—PPARG—urinary bladder cancer	0.0004	0.00209	CbGpPWpGaD
Carbimazole—TPO—Metabolism—CREBBP—urinary bladder cancer	0.000384	0.00201	CbGpPWpGaD
Carbimazole—CYP19A1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.000382	0.002	CbGpPWpGaD
Carbimazole—CYP19A1—Metabolism—TYMP—urinary bladder cancer	0.00038	0.00199	CbGpPWpGaD
Carbimazole—CYP19A1—Integrated Breast Cancer Pathway—TP53—urinary bladder cancer	0.00037	0.00194	CbGpPWpGaD
Carbimazole—CYP19A1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.000365	0.00192	CbGpPWpGaD
Carbimazole—CYP19A1—Metabolism—NAT2—urinary bladder cancer	0.000344	0.0018	CbGpPWpGaD
Carbimazole—TPO—Metabolism—PTGS2—urinary bladder cancer	0.000314	0.00165	CbGpPWpGaD
Carbimazole—CYP19A1—Metabolism—RRM2—urinary bladder cancer	0.000297	0.00156	CbGpPWpGaD
Carbimazole—CYP19A1—Metabolism—HPGDS—urinary bladder cancer	0.000275	0.00144	CbGpPWpGaD
Carbimazole—CYP19A1—Metabolism—ENO2—urinary bladder cancer	0.000275	0.00144	CbGpPWpGaD
Carbimazole—TPO—Metabolism—PTEN—urinary bladder cancer	0.000274	0.00144	CbGpPWpGaD
Carbimazole—CYP19A1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	0.000273	0.00143	CbGpPWpGaD
Carbimazole—CYP19A1—Metabolism—GSTT1—urinary bladder cancer	0.000267	0.0014	CbGpPWpGaD
Carbimazole—CYP19A1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	0.000263	0.00138	CbGpPWpGaD
Carbimazole—TPO—Metabolism—EP300—urinary bladder cancer	0.000261	0.00137	CbGpPWpGaD
Carbimazole—CYP19A1—Metabolism—NQO1—urinary bladder cancer	0.000222	0.00116	CbGpPWpGaD
Carbimazole—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	0.000215	0.00113	CbGpPWpGaD
Carbimazole—CYP19A1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	0.000188	0.000983	CbGpPWpGaD
Carbimazole—CYP19A1—Metabolism—GSTP1—urinary bladder cancer	0.000185	0.000969	CbGpPWpGaD
Carbimazole—CYP19A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	0.000179	0.000938	CbGpPWpGaD
Carbimazole—CYP19A1—Metabolism—TYMS—urinary bladder cancer	0.000172	0.000901	CbGpPWpGaD
Carbimazole—CYP19A1—Metabolism—GSTM1—urinary bladder cancer	0.00017	0.000891	CbGpPWpGaD
Carbimazole—CYP19A1—Metabolism—NCOR1—urinary bladder cancer	0.00017	0.000891	CbGpPWpGaD
Carbimazole—CYP19A1—Metabolism—GPX1—urinary bladder cancer	0.000163	0.000853	CbGpPWpGaD
Carbimazole—CYP19A1—Metabolism—ERCC2—urinary bladder cancer	0.00016	0.000837	CbGpPWpGaD
Carbimazole—CYP19A1—Metabolism—MTHFR—urinary bladder cancer	0.00015	0.000787	CbGpPWpGaD
Carbimazole—CYP19A1—Metabolism—PPARG—urinary bladder cancer	0.000122	0.000638	CbGpPWpGaD
Carbimazole—CYP19A1—Metabolism—CREBBP—urinary bladder cancer	0.000117	0.000613	CbGpPWpGaD
Carbimazole—CYP19A1—Metabolism—PTGS2—urinary bladder cancer	9.58e-05	0.000502	CbGpPWpGaD
Carbimazole—CYP19A1—Metabolism—PTEN—urinary bladder cancer	8.35e-05	0.000438	CbGpPWpGaD
Carbimazole—CYP19A1—Metabolism—EP300—urinary bladder cancer	7.97e-05	0.000418	CbGpPWpGaD
